Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis.
about
Clinical management of regorafenib in the treatment of patients with advanced colorectal cancerTherapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinomaRisk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysisDrug-induced glomerular disease: direct cellular injury.The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell CarcinomaIncidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patientsInfluence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer PatientsIncidence and risk of hypertension associated with cabozantinib in cancer patients: a systematic review and meta-analysis.Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.Predictive factor and antihypertensive usage of tyrosine kinase inhibitor-induced hypertension in kidney cancer patients.NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysisA model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080Residual renal function after partial or radical nephrectomy for renal cell carcinoma.Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.Non-interventional management of resistant hypertension.Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.A gist of gastrointestinal stromal tumors: A review.Common secondary causes of resistant hypertension and rational for treatmentA phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategiesCardiotoxicity of molecularly targeted agentsTreatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors.Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents.Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinomaManagement of antiangiogenic therapy-induced hypertension.Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials.Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.Systemic cancer therapy: achievements and challenges that lie aheadCardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review.Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis.
P2860
Q26821956-D9C990F1-5A75-4046-BF43-9C179FC55AE7Q27013665-140E4A4E-1199-4F62-A97D-9A8DB77BCA77Q27026453-327705ED-974C-4195-A189-C5672CC53CD7Q27692666-D320B387-4787-4163-B31C-39807D60DAD7Q27851744-E2EFC360-D2AC-4816-8B91-DE37760DAC71Q28066747-19D48272-945A-44FC-8C92-45E88B2BFE17Q28079328-7C122259-2CDE-4116-84A5-4D85A2B367E0Q28080163-E7F4419E-06B1-4B7B-B54D-49C19DB2F9F8Q30250303-E626AE70-0466-4019-9318-87174D121C3AQ30417015-40C97E19-38BE-438B-A456-64EEE02DA108Q30426853-0862773E-BA25-4EDE-9CCD-9C0D3DBD9CB9Q33778275-FACFF5BF-9965-4658-8957-C0D6A8624D67Q33921067-02F9BC5B-BD86-4728-872F-865866A5556AQ33926377-910D026D-431A-4956-B0D0-91FBB17F753EQ34063604-6EB69596-75B3-4A5A-997E-81BE91741748Q34179292-3B2A2532-5783-46F6-BACD-662F7FF73295Q34245458-9E8F5530-8E5E-4A00-AC62-EA71893D9015Q34404475-F2D4667F-564D-4CC0-9860-4425201CE7EDQ34554398-8D6AD195-E8C0-4489-AFDD-327C9D86BD52Q34654203-5744D761-2B9A-4925-83A3-BB77F8D835EDQ34669789-F5C848EA-33E0-437B-877A-E3801D52FE42Q34724614-F85E9A18-85B7-4559-8C80-F87BD3D1A5ACQ34916352-94B12571-8B81-4427-B8AB-F01B3C0230C5Q34943606-5E8B742E-2673-42F7-9090-B1CDF5D821B6Q35002540-BDB897E2-036F-4D1D-919A-A72EE4AD8AA6Q35584182-F67304A4-7B67-4B3F-A4D8-E2DEBA78E061Q35878459-BB93A0CB-E159-4C13-A222-9BF05167E8A7Q36106439-00E2AFE9-6FBC-4676-B82C-07BB545A7D1BQ36136849-FD27794D-97E6-4005-A356-7257DBBAE30AQ36150570-4A45F2B3-F3B3-48E2-86E3-DAA026440EFFQ36170252-316659B0-2031-4CE7-BA9B-7C80A8D0C2D0Q36316309-62C1D529-F3AB-487A-A8B1-C1A352D6AEE8Q36627125-D31C4A53-0B6A-4430-A355-1EACB4447DFAQ36729895-5E9C5A13-7137-4DFD-BE31-D174F47015A6Q36751861-D7A124A6-9D2F-4A79-AC51-567057E62CECQ36821958-BF27D7BD-BCEC-431F-8CA7-4438B5C8ACE6Q36891574-0AF9F113-CFBC-4A74-839B-97291344FB6FQ37038711-2B2731F3-18BE-4FD9-A1C8-B8EA209200B1Q37042424-03FD5801-8FCD-4506-B5D4-B2C23FF4E38BQ37161889-1E6683FA-F15D-4075-BCCF-F10FF58D04DE
P2860
Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Risk of hypertension and renal ...... atic review and meta-analysis.
@en
Risk of hypertension and renal ...... atic review and meta-analysis.
@nl
type
label
Risk of hypertension and renal ...... atic review and meta-analysis.
@en
Risk of hypertension and renal ...... atic review and meta-analysis.
@nl
prefLabel
Risk of hypertension and renal ...... atic review and meta-analysis.
@en
Risk of hypertension and renal ...... atic review and meta-analysis.
@nl
P2093
P2860
P31
P1433
P1476
Risk of hypertension and renal ...... atic review and meta-analysis.
@en
P2093
Kathleen Stergiopoulos
Shenhong Wu
Xiaolei Zhu
P2860
P356
10.1080/02841860802314720
P577
2009-01-01T00:00:00Z